BioCentury
ARTICLE | Finance

Performance Counts

Europe's best-performing biotechs took on more risk, raised the most money

May 31, 2010 7:00 AM UTC

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond.

While in total these private and public biotechs also have registered the largest amount of money needed to finance the next three years of runway - €3.5 billion ($4.8 billion) - the individual companies are showing a continued trend toward burning less money to advance their programs...